Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.22.1
Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]      
Revenues $ 761,319 $ 478,520 $ 460,739
Cost of revenues 307,713 236,493 388,265
Amortization of intangible assets 428,434 428,431 470,773
Gross loss (income) (25,172) 186,404 398,299
Operating expenses:      
Research and development 926,697 987,444 1,090,295
Less - research and development grants (525,838) (256,423) (314,652)
Research and development, net 400,859 731,021 775,643
Sales and marketing 673,986 673,983 550,008
General and administrative 1,414,370 1,319,239 1,297,711
Goodwill impairment 265,089 161,381
Total operating expenses 2,754,304 2,724,243 2,784,743
Operating loss 2,729,132 2,910,647 3,183,042
Financial expenses (income), net 9,814,605 1,042,358 (1,210,484)
Net loss $ 12,543,737 $ 3,953,005 $ 1,972,558
Net loss per ordinary share:      
Basic and diluted net loss per ordinary share (in Dollars per share) $ 0.49 $ 0.16 $ 0.09
Weighted average number of ordinary shares used in computing basic and diluted net loss per ordinary share (in Shares) 25,581,000 24,071,186 23,142,850